Leiters and Prodigy Health Enter into National Sales and Marketing Agreement

Source: Leiters

Leiters and Prodigy Health have entered into a national sales and marketing agreement that will permit Prodigy Health to bring its ProdigyVision technology platform to the Leiters portfolio of 503B compounded sterile preparations in collaboration with the Leiters sales and marketing team.

Terms of the deal were not disclosed.

Leiters is a FDA-registered 503B outsourcing provider of hospital and ophthalmology compounded sterile preparations. Leiters provides outsourced medications across the continuum of healthcare including, hospitals, surgery centers, physician offices and clinics. 

“We are thrilled to partner with Prodigy Health, an outstanding leader in the specialty drug distribution market, to broaden our foot print in acute care by reaching more customers,” Robin Smith Hoke, Chief Executive Officer of Leiters, said in a company news release. “Leiters has been a trusted leader of compounded sterile preparations for nearly a century, and this partnership illustrates our unwavering commitment to deliver better medicine to more people.”

Prodigy Health leverages technology solutions in the hospital supply chain and connects hospitals to high-value, specialty pharmaceutical products through their innovative supply chain platform and services.

“Prodigy delivers peace of mind to hospital customers through ProdigyVision’s real time 503B inventory view at the time of order, so customers know their order will ship. We believe that by combining Prodigy’s technology and service platform with Leiters leadership’s deep experience in sterile pharmaceutical manufacturing and pharmacy supply chain will deliver an unmatched solution to hospitals nationwide,” Jon Houssian, Chief Executive Officer of Prodigy Health, said in the news release.


Related Content